Concomitant inhibition of janus kinases (JAKs) might be a rational approach to deepen clinical responses to ibrutinib3, 4 as cytokine signaling through JAKs can promote the growth and survival of CLL cells and is not prevented by BTK blockade.5, 6. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.